GlaxoSmithKline (GSK) is a science-led global health care company with a special purpose: to help people do more, feel better, live longer. In 2014, GSK signed a license agreement with Codexis for use of their proprietary CodeEvolver® protein engineering platform technology to develop novel enzymes for more efficient and sustainable manufacture of GSK’s pharmaceutical and health care products.
Merck is a leading global biopharmaceutical company that has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Under a 2015 technology transfer and licensing agreement, Codexis completed transfer of its proprietary CodeEvolver® protein engineering platform technology to enhance Merck’s capabilities by advancing and expanding the use of custom enzymes in pharmaceutical manufacturing processes.
Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutrition therapy to change the course of health for consumers, patients and its partners in health care. In 2017, Codexis and Nestlé Health Science entered into a strategic collaboration for multiple projects accessing Codexis’ CodeEvolver® protein engineering platform technology to fuel therapeutic and nutritional innovation. The partnership includes a Nestlé Health Science option for the global development of Codexis’ novel enzyme, CDX-6114, for the management of phenylketonuria (PKU). Nestlé Health Science has also secured strategic access to the CodeEvolver® technology for the discovery of biotherapeutics for other metabolic disorders and for the development of novel enzymes for medical nutrition and consumer care products.
Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in more than 30 locations worldwide. Since 2013, Codexis and Tate & Lyle have been working in deep collaboration to develop novel enzymes and efficient processes for the sustainable and economic manufacture of food ingredients. The latest success in this partnership is the commercialization, within only two years of initial concept discussions, of a multi-enzyme process for the production of Tasteva® M Stevia Sweetener – a naturally derived sweetener in high demand within the food & beverage industries.
Porton Pharma Solutions provides custom API development and cGMP manufacturing services to the global drug industry. In 2018, Codexis and Porton entered into a strategic collaboration to accelerate the creation and commercialization of new, low-cost sustainable manufacturing processes to supply small molecule pharmaceuticals. The partnership reduces costs by improving yields, eliminating processing steps, enhancing capital productivity and/or minimizing consumption of solvents or energy or downstream waste processing. Codexis licenses core elements of its biocatalyst technologies to Porton and provides preferential access to its CodeEvolver® protein engineering platform technology for the creation of new biocatalytic process solutions. In parallel, Porton pledges to utilize the CodeEvolver® technology team and to drive adoption of biocatalyst technologies into its custom contract development and manufacturing offerings.
Takeda is a global, values-based, R&D-driven global biopharmaceutical company headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. In March 2020, Codexis and Takeda signed a strategic collaboration and license agreement to advance novel gene therapies for rare genetic disorders. Under the terms of the agreement, Codexis will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using its CodeEvolver® protein engineering platform. Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders.
Alphazyme is an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes. On June 1, 2020, Codexis and Alphazyme announced a Co-Marketing & Enzyme Supply Collaboration Agreement for the production and co-marketing of enzymes for life science applications. Three enzymes were launched alongside the agreement – high-fidelity DNA polymerase, evolved T7 RNA polymerase, and reverse transcriptase – to prospective customers over the second and third quarters of 2020. This partnership will jointly promote and sell these enzymes as well as a suite of high-performance engineered enzymes currently under development to innovators in life science and diagnostic markets.
Molecular Assemblies is a private biotechnology company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. On June 23, 2020, Codexis and Molecular Assemblies announced a partnership to engineer enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA. In an interview with SynBioBeta, John Nicols and Mike Kamdar, the CEOs of Codexis and Molecular Assemblies, respectively, talked about the significance of enzymatic DNA synthesis and what this partnership means to synthetic biology and the entire biotechnology sector.
Contact us if you are interested in partnering with Codexis as we unlock the power of proteins® and deliver customized solutions.